By IDSE News Staff
The direct-acting antiviral sofosbuvir significantly reduced the risk for death and need for a transplant among hepatitis C patients with advanced liver disease, according to a study presented at the 2017 International Joint Congress of ILTS, ELITA & LICAGE, in Prague.
The team, led by clinical researchers at Intermountain Healthcare’s Intermountain Medical Center, in Salt Lake City, studied nearly 1,900 HCV patients and found that the number of patients needing